Browse TBC1D4

Summary
SymbolTBC1D4
NameTBC1 domain family, member 4
Aliases KIAA0603; AS160; DKFZp779C0666; Akt substrate of 160 kDa; NIDDM5; TBC (Tre-2, BUB2, CDC16) domain-containing ......
Chromosomal Location13q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Note=Isoform 2 shows a cytoplasmic perinuclear localization in a myoblastic cell line in resting and insulin-stimulated cells.
Domain PF11830 Domain of unknown function (DUF3350)
PF00640 Phosphotyrosine interaction domain (PTB/PID)
PF00566 Rab-GTPase-TBC domain
Function

May act as a GTPase-activating protein for RAB2A, RAB8A, RAB10 and RAB14. Isoform 2 promotes insulin-induced glucose transporter SLC2A4/GLUT4 translocation at the plasma membrane, thus increasing glucose uptake.

> Gene Ontology
 
Biological Process GO:0006906 vesicle fusion
GO:0010639 negative regulation of organelle organization
GO:0016050 vesicle organization
GO:0031338 regulation of vesicle fusion
GO:0031339 negative regulation of vesicle fusion
GO:0032868 response to insulin
GO:0032869 cellular response to insulin stimulus
GO:0043434 response to peptide hormone
GO:0044801 single-organism membrane fusion
GO:0048284 organelle fusion
GO:0051051 negative regulation of transport
GO:0060627 regulation of vesicle-mediated transport
GO:0061025 membrane fusion
GO:0071375 cellular response to peptide hormone stimulus
GO:0071417 cellular response to organonitrogen compound
GO:0090174 organelle membrane fusion
GO:0090630 activation of GTPase activity
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
Molecular Function GO:0005096 GTPase activator activity
GO:0008047 enzyme activator activity
GO:0017016 Ras GTPase binding
GO:0017137 Rab GTPase binding
GO:0030695 GTPase regulator activity
GO:0031267 small GTPase binding
GO:0051020 GTPase binding
GO:0060589 nucleoside-triphosphatase regulator activity
Cellular Component GO:0030659 cytoplasmic vesicle membrane
> KEGG and Reactome Pathway
 
KEGG hsa04919 Thyroid hormone signaling pathway
Reactome R-HSA-199991: Membrane Trafficking
R-HSA-1445148: Translocation of GLUT4 to the plasma membrane
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolTBC1D4
NameTBC1 domain family, member 4
Aliases KIAA0603; AS160; DKFZp779C0666; Akt substrate of 160 kDa; NIDDM5; TBC (Tre-2, BUB2, CDC16) domain-containing ......
Chromosomal Location13q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TBC1D4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolTBC1D4
NameTBC1 domain family, member 4
Aliases KIAA0603; AS160; DKFZp779C0666; Akt substrate of 160 kDa; NIDDM5; TBC (Tre-2, BUB2, CDC16) domain-containing ......
Chromosomal Location13q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TBC1D4 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTBC1D4
NameTBC1 domain family, member 4
Aliases KIAA0603; AS160; DKFZp779C0666; Akt substrate of 160 kDa; NIDDM5; TBC (Tre-2, BUB2, CDC16) domain-containing ......
Chromosomal Location13q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TBC1D4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.8690.0409
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.6910.676
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8710.418
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0330.91
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1340.951
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2450.93
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1620.693
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0560.975
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2490.902
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5340.642
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0170.522
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2250.0229
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TBC1D4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.37.4-2.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.17.71.41
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTBC1D4
NameTBC1 domain family, member 4
Aliases KIAA0603; AS160; DKFZp779C0666; Akt substrate of 160 kDa; NIDDM5; TBC (Tre-2, BUB2, CDC16) domain-containing ......
Chromosomal Location13q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TBC1D4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTBC1D4
NameTBC1 domain family, member 4
Aliases KIAA0603; AS160; DKFZp779C0666; Akt substrate of 160 kDa; NIDDM5; TBC (Tre-2, BUB2, CDC16) domain-containing ......
Chromosomal Location13q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TBC1D4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TBC1D4.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTBC1D4
NameTBC1 domain family, member 4
Aliases KIAA0603; AS160; DKFZp779C0666; Akt substrate of 160 kDa; NIDDM5; TBC (Tre-2, BUB2, CDC16) domain-containing ......
Chromosomal Location13q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TBC1D4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTBC1D4
NameTBC1 domain family, member 4
Aliases KIAA0603; AS160; DKFZp779C0666; Akt substrate of 160 kDa; NIDDM5; TBC (Tre-2, BUB2, CDC16) domain-containing ......
Chromosomal Location13q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TBC1D4 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTBC1D4
NameTBC1 domain family, member 4
Aliases KIAA0603; AS160; DKFZp779C0666; Akt substrate of 160 kDa; NIDDM5; TBC (Tre-2, BUB2, CDC16) domain-containing ......
Chromosomal Location13q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TBC1D4 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTBC1D4
NameTBC1 domain family, member 4
Aliases KIAA0603; AS160; DKFZp779C0666; Akt substrate of 160 kDa; NIDDM5; TBC (Tre-2, BUB2, CDC16) domain-containing ......
Chromosomal Location13q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TBC1D4 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.